Relaxin in Multiple Sclerosis (MS)

The goal of this study is to obtain baseline information on serum and cerebrospinal fluid
(CSF) relaxin and Sema4A levels in patients with MS, as well as to further study RXFP-1
receptor binding affinity for RLX in patients with active and clinically stable MS, and
further characterize the role of Sema4A in MS patients.

Inclusion Criteria:

- Subjects with suspected MS, who have had a clinical attack within the last 12 weeks,
have at least one gadolinium-enhancing lesion on brain or spinal cord MRI taken within
the prior 4 weeks, and for which they have not received any immunomodulating or
immunosuppressant medication.

- Subjects with clinically stable definite MS, with no evidence of clinical relapse for
at least the past 12 weeks, and have no gadolinium enhancing lesions on MRI in the
prior 4 weeks. These subjects will fulfill the Revised (2010) McDonald's Criteria for
the Diagnosis of MS.

- Subjects without evidence of inflammatory systemic or inflammatory central nervous
system disease, who require CSF removal for some other cause, such treatment of benign
intracranial hypertension or as part of the procedure for insertion of an intrathecal
medication delivery system.

Exclusion Criteria:

- Pregnancy